NASDAQ:AKBA
$0.670
(
-5.63%
)
Friday, 27th Jan 2023
Akebia Therapeutics Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $0.409 | $0.770 | Friday, 27th Jan 2023 AKBA stock ended at $0.670. This is 5.63% less than the trading day before Thursday, 26th Jan 2023. During the day the stock fluctuated 28.21% from a day low at $0.560 to a day high of $0.718. |
| 90 days | $0.243 | $0.770 | |
| 52 weeks | $0.241 | $2.93 |
Historical Akebia Therapeutics prices
| Date | Open | High | Low | Close | Volume |
| 2023-01-27 | $0.700 | $0.718 | $0.560 | $0.670 | 2 642 750 |
| 2023-01-26 | $0.730 | $0.730 | $0.701 | $0.710 | 1 737 203 |
| 2023-01-25 | $0.710 | $0.730 | $0.710 | $0.712 | 1 074 694 |
| 2023-01-24 | $0.710 | $0.750 | $0.701 | $0.722 | 1 400 125 |
| 2023-01-23 | $0.737 | $0.737 | $0.701 | $0.710 | 915 213 |
| 2023-01-20 | $0.700 | $0.745 | $0.690 | $0.737 | 1 194 736 |
| 2023-01-19 | $0.744 | $0.744 | $0.672 | $0.709 | 1 434 731 |
| 2023-01-18 | $0.728 | $0.770 | $0.710 | $0.719 | 1 631 937 |
| 2023-01-17 | $0.719 | $0.740 | $0.695 | $0.730 | 944 447 |
| 2023-01-13 | $0.681 | $0.728 | $0.680 | $0.695 | 1 031 648 |
| 2023-01-12 | $0.688 | $0.690 | $0.650 | $0.690 | 836 400 |
| 2023-01-11 | $0.650 | $0.688 | $0.632 | $0.670 | 982 100 |
| 2023-01-10 | $0.660 | $0.660 | $0.630 | $0.647 | 690 303 |
| 2023-01-09 | $0.640 | $0.694 | $0.633 | $0.645 | 1 340 000 |
| 2023-01-06 | $0.700 | $0.710 | $0.622 | $0.642 | 2 133 500 |
| 2023-01-05 | $0.639 | $0.688 | $0.626 | $0.670 | 2 319 861 |
| 2023-01-04 | $0.630 | $0.650 | $0.580 | $0.633 | 3 399 855 |
| 2023-01-03 | $0.585 | $0.651 | $0.550 | $0.623 | 3 899 374 |
| 2022-12-30 | $0.491 | $0.578 | $0.490 | $0.577 | 3 566 240 |
| 2022-12-29 | $0.423 | $0.540 | $0.423 | $0.506 | 4 686 238 |
| 2022-12-28 | $0.410 | $0.440 | $0.409 | $0.423 | 1 216 768 |
| 2022-12-27 | $0.420 | $0.440 | $0.412 | $0.412 | 1 369 246 |
| 2022-12-23 | $0.407 | $0.440 | $0.407 | $0.427 | 681 203 |
| 2022-12-22 | $0.406 | $0.450 | $0.404 | $0.411 | 1 869 794 |
| 2022-12-21 | $0.412 | $0.434 | $0.409 | $0.411 | 862 801 |
| 2022-12-20 | $0.399 | $0.446 | $0.384 | $0.420 | 1 990 372 |
| 2022-12-19 | $0.455 | $0.460 | $0.365 | $0.400 | 2 717 908 |
| 2022-12-16 | $0.440 | $0.479 | $0.430 | $0.442 | 3 357 121 |
| 2022-12-15 | $0.450 | $0.460 | $0.390 | $0.454 | 2 442 383 |
| 2022-12-14 | $0.428 | $0.480 | $0.392 | $0.453 | 3 589 417 |
| 2022-12-13 | $0.395 | $0.440 | $0.386 | $0.424 | 3 789 975 |
| 2022-12-12 | $0.308 | $0.408 | $0.308 | $0.373 | 3 834 057 |
| 2022-12-09 | $0.298 | $0.318 | $0.298 | $0.310 | 689 721 |
| 2022-12-08 | $0.309 | $0.310 | $0.293 | $0.300 | 1 786 806 |
| 2022-12-07 | $0.293 | $0.308 | $0.281 | $0.300 | 2 899 800 |
| 2022-12-06 | $0.290 | $0.295 | $0.281 | $0.285 | 2 378 911 |
| 2022-12-05 | $0.281 | $0.300 | $0.281 | $0.292 | 2 185 177 |
| 2022-12-02 | $0.297 | $0.300 | $0.279 | $0.290 | 1 852 802 |
| 2022-12-01 | $0.270 | $0.295 | $0.266 | $0.292 | 1 297 111 |
| 2022-11-30 | $0.250 | $0.280 | $0.250 | $0.271 | 2 298 848 |
| 2022-11-29 | $0.255 | $0.259 | $0.243 | $0.250 | 996 311 |
| 2022-11-28 | $0.260 | $0.260 | $0.250 | $0.251 | 947 177 |
| 2022-11-25 | $0.259 | $0.265 | $0.253 | $0.256 | 773 178 |
| 2022-11-23 | $0.260 | $0.267 | $0.253 | $0.261 | 720 317 |
| 2022-11-22 | $0.260 | $0.270 | $0.252 | $0.260 | 1 341 211 |
| 2022-11-21 | $0.258 | $0.265 | $0.250 | $0.255 | 884 142 |
| 2022-11-18 | $0.251 | $0.264 | $0.246 | $0.254 | 985 453 |
| 2022-11-17 | $0.257 | $0.269 | $0.243 | $0.265 | 2 472 249 |
| 2022-11-16 | $0.270 | $0.270 | $0.251 | $0.254 | 883 641 |
| 2022-11-15 | $0.262 | $0.275 | $0.252 | $0.259 | 1 273 967 |
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
